Description:Benzodiazepines(diazepam, lorazepam) are a category of medications that exert their effects on benzodiazepine receptors in the central nervous system. Certain benzodiazepines, such as alprazolam, clobazam, chlordiazepoxide, and others, are approved by the United States Food and Drug Administration (FDA). These drugs are crucial for the cessation of seizure activity, as they account for 1% to 2% of United States emergency department visits annually. Benzodiazepines may be administered for various indications, including, but not limited to, insomnia, acute status epilepticus, induction of amnesia, agitation, and anxiety, spastic, and seizure disorders.
Absorption: After oral administration, benzodiazepines are usually well absorbed from the gastrointestinal tract, except clorazepate, which undergoes decarboxylation in gastric juice before absorption. After intramuscular (IM) injection, the absorption of diazepam or Distribution: The benzodiazepines and their active metabolites avidly bind to plasma proteins. Plasma protein binding is approximately 70% for alprazolam, 85% for clonazepam, and 99% for diazepam. The concentration of benzodiazepines in the cerebrospinal fluid is approximately equal to that of free drugs in plasma. Diazepam is redistributed especially rapidly.Metabolism: Most benzodiazepines are metabolized extensively by hepatic CYP3A4 and CYP2C19. Lorazepam undergoes direct glucuronidation without cytochrome p450 metabolism. Elimination: Benzodiazepines and their metabolites are primarily excreted by the kidneys.

DETAILEDDESCRIPTIONOFTHEINVENTION

It is pharmacological safe with good bioavailability with least toxicity Chamomile and Ashwagandha. This review gives some phytochemicals as well as the detailed pharmacological information of Tectonagrandis. The main focus on the pharmacological potentials of Chamomile and Ashwagandha leaf which is very helpful to researcher to add more about this valuable plant. Apart from this still there are few options to investigate the unexplored potential of plant based on its uses.
Intrоduсtiоn:
Sedative-hypnotics are a class of drugs that work on the central nervous system (CNS) to produce a calming or drowsy effect and are often prescribed for insomnia, anxiety, and seizure disorders. They can be classified into three main categories: benzodiazepines, barbiturates, and Z-drugs (non-benzodiazepine hypnotics).
 Collection of plant materials
 Identification and Authentication
 Extraction of plant materials
• Drying: The collected bark were dried for 7 days at room temperature (27-37 oC). The shade drying was done to protect, the thermo-labile phytoconstituents, if any.
• Sieving: The shade dried leaves were coarsely powdered mechanically using commercial electrical stainless steel blender, and the powdered material was passed through sieve no. 20 to remove excessive mucilaginous hair and to obtain the fine powdered drug material.
• Soxhlation: The dried powdered plant materialwas extracted with solvents at 60 oC for 24 hours, using soxhlet apparatus. The extracts were then filtered and dried under vacuum.
 Qualitative analysis of the collected extracts for carbohydrates, proteins, alkaloids, glycosides, tannins, amino acids, phenols, flavonoids,steroids,triterpenoids etc.
All the experimental procedure and protocols used in the present study were reviewed and approved by the Institutional Animal Ethics Committee (IAEC) constituted under Committee for the Purpose of control and supervision of experiments on animals (CPCSEA). For this, study protocol (form no- Form B of CPCSEA) was prepared and submitted to the institutional ethics committee for approval to carry out experiments on animals.
Procurement and Housing of Animals:
The animals were housed in polyacrylic cages (38X23X10 cm) with not more than four animals per cage. The animals were housed in an air conditioned room and were kept in standard laboratory conditions under natural light and dark cycle (approximately 12 h light / 12 h dark cycle) and maintained humidity 60 ± 5% and an ambient temperature of 25 ± 2oC. The animals were allowed to free access to standard diet and water ad libitum and allowed to acclimatize for one week before the experiments. Commercial pellet diet contained 22 % Protein, 4% Fat, 4% Fiber, 36% Carbohydrates and 10% Ash w/w.
Acute toxicity studies of leave extracts were studied in female mice according to the guidelines for organization of economic cooperation and development (OECD 423). According to the guidelines, the female mice were used for the test. The animals were given the proper diet and kept in 12 hours light and 12 hours dark cycle. Now the mice were kept on over-night fasting before conducting the experiment. Extracts were administered to the animals at different doses i.e. 5, 50, 500, 2000, mg/kg body weight. Now the mortality and the toxicity sign were observed continuously for 1 hour and then for 24 hours after administration of extracts (OECD guidelines, 2006).
Pharmacological studies:
 To study on Ethanol and aqueous extracts of leaf extracts of chamomile and Ashwagandha for Locomotor activity for Actophotometer and muscle relaxant activity for rota rod apparatus in vitro models in mice.
 Statistical analysis
, Claims:The Phytochemical screening of ethanol and aqueous extracts of leaf extracts of Chamomile and Ashwagandha.
Claim: Qualitative analysis of the collected extracts for carbohydrates, proteins, alkaloids,glycosides, tannins, amino acids, phenols, flavonoids,steroids,triterpenoids etc.
Extraction of plant materials:
Claim: Drying: The collected bark were dried for 7 days at room temperature (27-37 oC). The shade drying was done to protect, the thermo-labile phytoconstituents, if any.
Sieving: The shade dried leaves were coarsely powdered mechanically using commercial electrical stainless steel blender, and the powdered material was passed through sieve no. 20 to remove excessive mucilaginous hair and to obtain the fine powdered drug material.
Soxhlation: The dried powdered plant materialwas extracted with solvents at 60 oC for 24 hours, using soxhlet apparatus. The extracts were then filtered and dried under vacuum.
Procurement of animal house:
Claim: The animals were housed in polyacrylic cages (38X23X10 cm) with not more than four animals per cage. The animals were housed in an air conditioned room and were kept in standard laboratory conditions under natural light and dark cycle (approximately 12 h light / 12 h dark cycle) and maintained humidity 60 ± 5% and an ambient temperature of 25 ± 2oC. The animals were allowed to free access to standard diet and water ad libitum and allowed to acclimatize for one week before the experiments.
Acute toxicity studies:
Claim:Acute toxicity studies of leave extracts were studied in female mice according to the guidelines for organization of economic cooperation and development (OECD 423). According to the guidelines, the female mice were used for the test. The animals were given the proper diet and kept in 12 hours light and 12 hours dark cycle.
Claim:By enhanсingtheзоlubility andзkinpenetratiоnоf ClaззIIdrugз, ethозоmalfоrmulatiоnзсоntributetоhigherdrugсоnсentratiоnзatthetarget зite, imprоving therapeutiсоutсоmeзand minimizing зideeffeсtзaззосiated with fluсtuatiоnз in drug levelз.
Pharmacological studies:
Claim: To study on Ethanol and aqueous extracts of leaf extracts of chamomile and Ashwagandha for Locomotor activity for Actophotometer and muscle relaxant activity for rota rod apparatus in vitro models in mice.

Locomotor activity:
Claim:Effect of Drugs on Locomotor Activity Using Actophotometer
Preparation of Animals: - Acclimate the rodents to the laboratory environment for at least one hour before the experiment. - Handle the animals gently to minimize stress. 2. Baseline Measurements: - Place each rodent in the actophotometer for a specified period (e.g., 5 minutes) to record baseline locomotor activity. - The actophotometer counts the number of times the animal inThe actophotometer counts the number of times the animal interrupts the light beams, giving a measure of locomotor activity. 3. Drug Administration: - Administer the test drug intraperitoneally or orally, depending on the experimental design. - Administer a control solution (e.g., saline) to the control group. 4. Observation and Data Recording: - Place the animals in the actophotometer at specific time intervals (e.g., 15, 30, 60, 90 minutes) after drug administration. - Record the locomotor activity (number of beam interruptions) during a fixed observation period (e.g., 5 minutes). 5. Post-Experiment Care: - Monitor the animals until they fully recover from any drug effects. - Provide appropriate post-experiment care as per ethical guidelines.
Results:
claim- A decrease in beam interruptions indicates reduced locomotor activity, often due to CNS depressant effects of the drug. - Conversely, an increase in beam interruptions would indicate increased activity, as seen with CNS stimulants. 1.locomotor activity 2. Dose-Response Relationship: - Higher doses of CNS depressants typically result in greater reductions in locomotor activity. - Higher doses of CNS stimulants result in increased locomotor activity until toxic effects occur. 3. Behavioral Observations: - Note any additional behavioral changes such as sedation, hyperactivity, stereotypic behaviors, or other side effects.
Rota rod apparatus:
Claim: Screening of Muscle Relaxant Activity Using Rota-Rod Apparatus.
The Rota-Rod apparatus is used to evaluate the muscle relaxant activity of compounds by measuring the time an animal can remain on a rotating rod. Muscle relaxants typically reduce the time the animal can maintain its grip and balance on the rodAnimal Preparation 1. Acclimatize the mice to the laboratory conditions for at least one week before the experiment. 2. Fast the mice overnight with free access to water prior to the experiment.
Experimental Groups:
Claim:Divide the mice into the following groups, with a minimum of six animals per group: 1. Control group: Receive saline or vehicle 2. Standard group: Receive a standard muscle relaxant (e.g., diazepam) 3. Test groups: Receive different doses of the test compound Administration of Compounds: 1. Administer the test compound, standard muscle relaxant, or vehicle intraperitoneally (i.p.) according to the group designation. 2. Allow 30 minutes for absorption.
Training on the Rota-Rod:
Claim:1. Train the mice on the Rota-Rod apparatus at a constant speed (e.g., 10 rpm) for threeconsecutive trials of 2 minutes each, with a rest period of at least 15 minutes between trials. 2. Only mice that can remain on the rotating rod for at least 180 seconds during the training session should be included in the study.
Testing for Muscle Relaxant Activity:
Claim: 1. Place each mouse on the rotating rod set at a constant speed (e.g., 10 rpm). 2. Record the time each mouse stays on the rotating rod (fall-off time) up to a maximum of 180 seconds. 3. Perform three trials per mouse with at least 15 minutes rest between trials. 4. Record the fall-off time for each trial. Calculation of Muscle Relaxant Activity:
Calculate the mean fall-off time for each mouse. 2. Compare the mean fall-off times of the test and standard groups with the control group. 3. A significant reduction in fall-off time compared to the control group indicates muscle relaxant activity.
Results and Discussion:
Claim:1. Present the data in a table showing the fall-off time for each mouse in all groups. 2. Calculate and present the mean fall-off time for each group along with the standard deviation. 3. Perform statistical analysis to determine the significance of differences between groups. 4. Discuss the results, comparing the muscle relaxant activity of the test compound with thecontrol and standard groups.
A significant reduction in fall-off time compared to the control group indicates muscle relaxant activity.
Safety and Ethical Considerations:
Claim: 1. Ensure all experimental procedures involving animals comply with institutional and national ethical guidelines for the care and use of laboratory animals. 2. Handle all animals with care and minimize their distress. 3. Dispose of all biological waste according to safety guidelines.
Conclusion: Summarize the findings, stating whether the test compound demonstrated significant muscle relaxant activity and how it compared to the standard muscle relaxant.